Free Trial

Inhibikase Therapeutics (IKT) SEC Filings & 10K Form

Inhibikase Therapeutics logo
$2.97 -0.29 (-8.90%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$2.94 -0.04 (-1.18%)
As of 02/21/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Inhibikase Therapeutics SEC Filings

DateFilerForm TypeView
02/19/2025
7:16 PM
Freeman Roy Lester (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:18 PM
Bellini Roberto (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:19 PM
Inhibikase Therapeutics (Issuer)
Kush Arvind (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:24 PM
Inhibikase Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/19/2025
7:26 PM
Inhibikase Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:00 PM
BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:06 PM
BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4/A
02/19/2025
7:11 PM
Canner David (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:11 PM
Inhibikase Therapeutics (Issuer)
Munshi Amit (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2025
7:09 AM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
8:04 PM
ADAR1 Capital Management, LLC (Filed by)
Inhibikase Therapeutics (Subject)
Form SCHEDULE 13G
02/14/2025
4:35 PM
ARMISTICE CAPITAL, LLC (Filed by)
Inhibikase Therapeutics (Subject)
Form SCHEDULE 13G/A
02/14/2025
2:45 PM
Fairmount Funds Management LLC (Filed by)
Inhibikase Therapeutics (Subject)
Form SCHEDULE 13G/A
02/04/2025
3:06 PM
Inhibikase Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/29/2025
3:05 PM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/22/2025
3:05 PM
BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2025
3:05 PM
Inhibikase Therapeutics (Issuer)
Werner Milton H. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2025
3:05 PM
Freeman Roy Lester (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2025
3:05 PM
Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2025
11:15 PM
Inhibikase Therapeutics (Filer)
Form EFFECT
01/10/2025
3:37 PM
Inhibikase Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
01/07/2025
5:39 PM
Freeman Roy Lester (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
5:43 PM
Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
5:47 PM
Inhibikase Therapeutics (Issuer)
Werner Milton H. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
5:38 PM
BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
5:06 AM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
11:15 PM
Inhibikase Therapeutics (Filer)
Form EFFECT
12/05/2024
3:47 PM
Inhibikase Therapeutics (Filer)
Form 424B3
12/05/2024
3:50 PM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2024
5:24 AM
Inhibikase Therapeutics (Filer)
Form S-3/A
11/18/2024
3:49 PM
Inhibikase Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/14/2024
7:30 AM
Inhibikase Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/08/2024
3:07 PM
Inhibikase Therapeutics (Filer)
Form PRE 14A
10/28/2024
4:26 PM
Inhibikase Therapeutics (Subject)
SP IKT Holdings LLC (Filed by)
Form SC 13G
10/28/2024
3:00 PM
Inhibikase Therapeutics (Subject)
Soleus Private Equity Fund III, L.P. (Filed by)
Form SC 13G
10/25/2024
4:52 PM
Inhibikase Therapeutics (Issuer)
Sands Capital Life Sciences Pulse Fund II, L.P. (Reporting)
Sands Capital Ventures, LLC (Reporting)
SANDS FRANK M. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/25/2024
4:50 PM
Inhibikase Therapeutics (Subject)
Sands Capital Life Sciences Pulse Fund II, L.P. (Filed by)
Form SC 13G
10/23/2024
6:58 PM
Canner David (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
6:35 PM
Bellini Roberto (Reporting)
Inhibikase Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/23/2024
6:36 PM
Inhibikase Therapeutics (Issuer)
Munshi Amit (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/23/2024
6:38 PM
Canner David (Reporting)
Inhibikase Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
Elon’s “New Gold” (Ad)

MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.

I reveal all of the details here.
10/23/2024
6:40 PM
Inhibikase Therapeutics (Issuer)
Kush Arvind (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/23/2024
6:43 PM
Inhibikase Therapeutics (Issuer)
Munshi Amit (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
6:49 PM
Inhibikase Therapeutics (Issuer)
Kush Arvind (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
6:53 PM
Bellini Roberto (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:15 PM
Inhibikase Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13G
10/21/2024
8:13 PM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2024
6:00 PM
Fairmount Funds Management LLC (Filed by)
Inhibikase Therapeutics (Subject)
Form SC 13G
10/17/2024
3:05 PM
COMMODORE CAPITAL LP (Filed by)
Inhibikase Therapeutics (Subject)
Form SC 13G
10/10/2024
4:31 PM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2024
7:40 AM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/05/2024
8:21 PM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/18/2024
4:23 PM
Dion Gisele (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2024
4:27 PM
GRINT PAUL C (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2024
4:18 PM
Freeman Roy Lester (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2024
4:20 PM
BERMAN DENNIS N (Reporting)
Inhibikase Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2024
8:25 PM
Inhibikase Therapeutics (Filer)
Form 424B3
06/26/2024
11:15 PM
Inhibikase Therapeutics (Filer)
Form EFFECT
06/21/2024
3:30 PM
Inhibikase Therapeutics (Filer)
Form DEFA14A
06/20/2024
5:06 PM
Inhibikase Therapeutics (Filer)
Form DEF 14A
06/18/2024
4:27 PM
Inhibikase Therapeutics (Filer)
Form S-1
Registration statement under Securities Act of 1933  
06/10/2024
3:20 PM
Inhibikase Therapeutics (Filer)
Form PRE 14A
05/22/2024
7:55 AM
Inhibikase Therapeutics (Filer)
Form 424B5
05/20/2024
7:55 AM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/20/2024
6:09 AM
Inhibikase Therapeutics (Filer)
Form 424B5
05/15/2024
6:56 AM
Inhibikase Therapeutics (Filer)
Form RW
05/09/2024
1:41 PM
Inhibikase Therapeutics (Filer)
Form S-1/A
04/30/2024
7:17 AM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/26/2024
3:20 PM
Inhibikase Therapeutics (Filer)
Form ARS
04/26/2024
3:15 PM
Inhibikase Therapeutics (Filer)
Form DEF 14A
04/25/2024
3:29 PM
Inhibikase Therapeutics (Filer)
Form S-1/A
04/19/2024
4:14 PM
Inhibikase Therapeutics (Filer)
Form S-1
Registration statement under Securities Act of 1933  
04/18/2024
8:46 PM
Inhibikase Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/02/2024
4:12 PM
Inhibikase Therapeutics (Filer)
Form 8-K/A
04/02/2024
4:12 PM
Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/02/2024
4:14 PM
Inhibikase Therapeutics (Issuer)
Lees-Rolfe Garth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NYSE:IKT) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners